- Acorda Therapeutics Inc ACOR has entered into distribution and supply agreements with Esteve Pharmaceuticals S.A. to commercialize Inbrija 33 mg (levodopa inhalation powder, hard capsules) in Spain.
- Inbrija is indicated in the E.U. for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
- Under the terms of the supply agreement, Acorda will receive a double-digit percentage of the selling price of Inbrija.
- Esteve has exclusive distribution rights to Inbrija in the territory, and it will launch the product in Spain in Q4 of 2022.
- Price Action: ACOR shares are up 49.3% at $5.69 during the premarket session on the last check Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareContractsMoversTrading IdeasGeneralBriefsParkinson’s Disease
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
